Hedge Fund ValueAct Bullish On Valeant Pharmaceuticals Intl Inc (VRX) - Letter - Hedge Fund Alpha (formerly ValueWalk Premium)

Hedge Fund ValueAct Bullish On Valeant Pharmaceuticals Intl Inc (VRX) – Letter

Valeant Pharmaceuticals Intl Inc has many well-known and vocal supporters in the hedge fund industry. Bill Ackman is perhaps the most notable of these advocates, due to the hedge fund billionaire’s oversized position in the former market darling. Jeffrey Ubben’s ValueAct Capital also owns a significant stake in the drug maker. According to the fund’s most recent 13F filing, ValueAct owned just under 15 million shares of Valeant at the end of the fourth quarter, around 10.6% of the hedge fund’s equity portfolio at the time making it the fund’s second-largest holding after Microsoft (21.8% of the fund’s equity portfolio)....

This content is exclusively for paying members of Hedge Fund Alpha

Gain Exclusive Access to the Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Get Started Now with a FREE 7-Day Trial🔻

If you are a current Hedge Fund Alpha member and are having an account error please clear cache and cookies. If that does not work, email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Watch a FREE Behind the Scenes Training on the 3 Secrets to Finding Small Cap Stock Opportunities with Massive Growth Potential in 2024.

Click here to get the training